Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Crucial Meetings With EMA Due For Travere/Vifor’s Sparsentan & Minoryx’s Leriglitazone

Executive Summary

Developers of three new drugs, including two orphan medicines, that are nearing the final stages of their EU regulatory review cycle could be asked to explain why the European Medicines Agency should recommend approval of their products.

You may also be interested in...

AstraZeneca’s Danicopan Among Four Orphans Up For EU Approval Decision

The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.

EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan

The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.

EMA Thumbs Up For HyQvia As Maintenance Therapy For Rare Neurological Disorder

The European Medicines Agency has recommended in favor of allowing new uses of four already-approved drugs and suspending the marketing authorization of several generics tested by an Indian-based CRO. 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts